AUB ScholarWorks

Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience

Show simple item record El-Beshlawy A. Manz C. Naja M. Eltagui M. Tarabishi C. Youssry I. Sobh H. Hamdy M. Sharaf I. Mostafa A. Shaker O. Hoffbrand A.V. Taher A.
dc.contributor.editor Jul-2008 2017-10-05T15:37:29Z 2017-10-05T15:37:29Z 2008
dc.identifier 10.1007/s00277-008-0471-2
dc.identifier.issn 09395555
dc.description.abstract Patients with thalassemia major requiring regular blood transfusions accumulate iron that is toxic to the heart, liver, and endocrine systems. The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP. Sixty-six patients were randomized into three treatment arms: daily DFP combined with DFO twice weekly; daily DFP only; and DFO only 5 days-week. Fifty-six patients completed the 54 weeks and were assessed by different indices. A significant reduction of liver iron concentration and serum ferritin was observed in all three arms while significant reduction of liver iron score was observed in patients on combination therapy only. Cardiac function did not significantly change in any arm. Compliance improved in patients who received combined therapy. Toxicity of DFP was mild to moderate and acceptable; most commonly, transient arthropathy and nausea-vomiting were observed. Thus, combination therapy has shown to be effective in reducing iron overload in thalassemia patients. © Springer-Verlag 2008.
dc.format.extent Pages: (545-550)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: Annals of Hematology; Publication Year: 2008; Volume: 87; no. 7; Pages: (545-550);
dc.source Scopus
dc.title Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience
dc.type Article
dc.contributor.affiliation El-Beshlawy, A., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Manz, C., Clinical Research and Development, Lipomed AG, Arlesheim, Switzerland
dc.contributor.affiliation Naja, M., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Eltagui, M., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Tarabishi, C., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Youssry, I., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Sobh, H., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Hamdy, M., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Sharaf, I., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Mostafa, A., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Shaker, O., Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt
dc.contributor.affiliation Hoffbrand, A.V., Royal Free Hospital, London, United Kingdom
dc.contributor.affiliation Taher, A., American University of Beirut Medical Center, Beirut, Lebanon, Chronic Care Center, Hazmieh, Lebanon
dc.contributor.authorAddress El-Beshlawy, A.; Faculty of Medicine, Cairo University, 32 Falaky Street, Cairo, Egypt; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials El-Beshlawy, A
dc.contributor.authorInitials Manz, C
dc.contributor.authorInitials Naja, M
dc.contributor.authorInitials Eltagui, M
dc.contributor.authorInitials Tarabishi, C
dc.contributor.authorInitials Youssry, I
dc.contributor.authorInitials Sobh, H
dc.contributor.authorInitials Hamdy, M
dc.contributor.authorInitials Sharaf, I
dc.contributor.authorInitials Mostafa, A
dc.contributor.authorInitials Shaker, O
dc.contributor.authorInitials Hoffbrand, AV
dc.contributor.authorInitials Taher, A
dc.contributor.authorReprintAddress El-Beshlawy, A (reprint author), Cairo Univ, Fac Med, 32 Falaky St, Cairo, Egypt.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Anderson LJ, 2002, LANCET, V360, P516, DOI 10.1016-S0140-6736(02)09740-4; Angelucci E, 2000, NEW ENGL J MED, V343, P327, DOI 10.1056-NEJM200008033430503; Balveer K, 2000, Med J Malaysia, V55, P493; Borgna-Pignatti C, 2006, BLOOD, V107, P3733, DOI 10.1182-blood-2005-07-2933; Cohen AR, 2000, BRIT J HAEMATOL, V108, P305; Daar S, 2006, ANN HEMATOL, V85, P315, DOI 10.1007-s00277-005-0075-z; Giardina PJ, 2001, SEMIN HEMATOL, V38, P360, DOI 10.1016-S0037-1963(01)90030-7; Grady RW, 2000, BLOOD, V96, p604A; Hoffbrand AV, 2005, BEST PRACT RES CL HA, V18, P299, DOI 10.1016-j.beha.2004.08.026; Kattamis A, 2006, BLOOD CELL MOL DIS, V36, P21, DOI 10.1016-j.bcmd.2005.11.002; Link G, 2001, J LAB CLIN MED, V138, P130, DOI 10.1067-mlc.2001.116487; Mourad FH, 2003, BRIT J HAEMATOL, V121, P187, DOI 10.1046-j.1365-2141.2003.04240.x; Origa R, 2005, HAEMATOL-HEMATOL J, V90, P1309; Peng CT, 2003, EUR J HAEMATOL, V70, P392, DOI 10.1034-j.1600-0609.2003.00071.x; Pennell DJ, 2006, BLOOD, V107, P3738, DOI 10.1182-blood-2005-07-2948; Tanner MA, 2007, CIRCULATION, V115, P1876, DOI 10.1161-CIRCULATIONAHA.106.648790; Wonke B, 1998, BRIT J HAEMATOL, V103, P361
dc.description.citedCount 19
dc.description.citedTotWOSCount 20
dc.description.citedWOSCount 19
dc.format.extentCount 6
dc.identifier.coden ANHEE
dc.identifier.pubmedID 18351337
dc.identifier.scopusID 44449104925
dc.publisher.address 233 SPRING ST, NEW YORK, NY 10013 USA
dc.relation.ispartOfISOAbbr Ann. Hematol.
dc.relation.ispartOfIssue 7
dc.relation.ispartofPubTitle Annals of Hematology
dc.relation.ispartofPubTitleAbbr Ann. Hematol.
dc.relation.ispartOfVolume 87
dc.source.ID WOS:000256088800004
dc.type.publication Journal
dc.subject.otherAuthKeyword Combination therapy
dc.subject.otherAuthKeyword Efficacy
dc.subject.otherAuthKeyword Egypt
dc.subject.otherAuthKeyword Monotherapy
dc.subject.otherAuthKeyword Thalassemia major
dc.subject.otherChemCAS deferiprone, 30652-11-0
dc.subject.otherChemCAS deferoxamine, 70-51-9
dc.subject.otherChemCAS ferritin, 9007-73-2
dc.subject.otherChemCAS iron, 14093-02-8, 53858-86-9, 7439-89-6
dc.subject.otherChemCAS Deferoxamine, 70-51-9
dc.subject.otherChemCAS Ferritins, 9007-73-2
dc.subject.otherChemCAS Iron Chelating Agents
dc.subject.otherChemCAS Pyridones
dc.subject.otherChemCAS deferiprone, 30652-11-0
dc.subject.otherIndex deferiprone
dc.subject.otherIndex deferoxamine
dc.subject.otherIndex ferritin
dc.subject.otherIndex iron
dc.subject.otherIndex adolescent
dc.subject.otherIndex adult
dc.subject.otherIndex agranulocytosis
dc.subject.otherIndex allergy
dc.subject.otherIndex anorexia
dc.subject.otherIndex arthropathy
dc.subject.otherIndex article
dc.subject.otherIndex backache
dc.subject.otherIndex blood transfusion
dc.subject.otherIndex bone pain
dc.subject.otherIndex child
dc.subject.otherIndex clinical trial
dc.subject.otherIndex combination chemotherapy
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug withdrawal
dc.subject.otherIndex echocardiography
dc.subject.otherIndex female
dc.subject.otherIndex ferritin blood level
dc.subject.otherIndex fever
dc.subject.otherIndex heart function
dc.subject.otherIndex human
dc.subject.otherIndex insomnia
dc.subject.otherIndex iron overload
dc.subject.otherIndex jaundice
dc.subject.otherIndex knee disease
dc.subject.otherIndex liver level
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex monotherapy
dc.subject.otherIndex myalgia
dc.subject.otherIndex nausea
dc.subject.otherIndex neutropenia
dc.subject.otherIndex patient compliance
dc.subject.otherIndex priority journal
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex side effect
dc.subject.otherIndex skin allergy
dc.subject.otherIndex skin swelling
dc.subject.otherIndex skin toxicity
dc.subject.otherIndex thalassemia major
dc.subject.otherIndex vomiting
dc.subject.otherIndex weakness
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Blood Transfusion
dc.subject.otherIndex Chelation Therapy
dc.subject.otherIndex Child
dc.subject.otherIndex Child, Preschool
dc.subject.otherIndex Deferoxamine
dc.subject.otherIndex Drug Administration Schedule
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Egypt
dc.subject.otherIndex Female
dc.subject.otherIndex Ferritins
dc.subject.otherIndex Humans
dc.subject.otherIndex Iron Chelating Agents
dc.subject.otherIndex Iron Overload
dc.subject.otherIndex Liver
dc.subject.otherIndex Male
dc.subject.otherIndex Patient Compliance
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Pyridones
dc.subject.otherIndex Thalassemia
dc.subject.otherKeywordPlus COMBINED THERAPY
dc.subject.otherKeywordPlus BETA-THALASSEMIA
dc.subject.otherKeywordPlus MYOCARDIAL IRON
dc.subject.otherKeywordPlus MAJOR PATIENTS
dc.subject.otherKeywordPlus DEFERIPRONE
dc.subject.otherKeywordPlus DESFERRIOXAMINE
dc.subject.otherKeywordPlus DEFEROXAMINE
dc.subject.otherKeywordPlus TRIAL
dc.subject.otherKeywordPlus OVERLOAD
dc.subject.otherKeywordPlus STORES
dc.subject.otherWOS Hematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account